Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.

Schmid S, Klingbiel D, Aeppli S, Britschgi C, Gautschi O, Pless M, Rothschild S, Wannesson L, Janthur W, Foerbs D, Demmer I, Jochum W, Früh M.

Lung Cancer. 2019 Apr;130:149-155. doi: 10.1016/j.lungcan.2019.02.020. Epub 2019 Feb 19.

PMID:
30885336
2.

A Variant of a Killer Cell Immunoglobulin-like Receptor is Associated with Resistance to PD-1 Blockade in Lung Cancer.

Trefny MP, Rothschild SI, Uhlenbrock F, Rieder D, Kasenda B, Stanczak MA, Berner F, Kashyap AS, Kaiser M, Herzig P, Poechtrager S, Thommen DS, Geier F, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz KD, Zippelius A, Läubli H.

Clin Cancer Res. 2019 Feb 14. pii: clincanres.3041.2018. doi: 10.1158/1078-0432.CCR-18-3041. [Epub ahead of print]

PMID:
30765392
3.

Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.

Papachristofilou A, Hipp MM, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Bischoff H, Geißler M, Griesinger F, Kallen KJ, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong HS, Koch SD, Gnad-Vogt U, Zippelius A.

J Immunother Cancer. 2019 Feb 8;7(1):38. doi: 10.1186/s40425-019-0520-5.

4.

Prognostic impact of polypharmacy and drug interactions in patients with advanced cancer.

Hoemme A, Barth H, Haschke M, Krähenbühl S, Strasser F, Lehner C, von Kameke A, Wälti T, Thürlimann B, Früh M, Driessen C, Joerger M.

Cancer Chemother Pharmacol. 2019 Apr;83(4):763-774. doi: 10.1007/s00280-019-03783-9. Epub 2019 Jan 25.

PMID:
30684020
5.

Lung cancer and smoking trends in the young in Switzerland: a study based on data of the National Institute for Cancer Epidemiology and Registration and of the Swiss Health Surveys.

Mousavi SM, Schmid S, Cerny T, Früh M.

Swiss Med Wkly. 2018 Dec 30;148:w14708. doi: 10.4414/smw.2018.14708. eCollection 2018 Dec 17.

6.

Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.

Hasan Ali O, Berner F, Bomze D, Fässler M, Diem S, Cozzio A, Jörger M, Früh M, Driessen C, Lenz TL, Flatz L.

Eur J Cancer. 2019 Jan;107:8-14. doi: 10.1016/j.ejca.2018.11.009. Epub 2018 Dec 7.

7.

Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment.

Diem S, Fässler M, Ali OH, Siano M, Niederer R, Berner F, Roux GA, Ackermann CJ, Schmid S, Güsewell S, Früh M, Flatz L.

Cancer Manag Res. 2018 Nov 8;10:5537-5544. doi: 10.2147/CMAR.S179767. eCollection 2018.

8.

[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example].

Griesinger F, Radke S, Lüers A, Deschler-Baier B, Kimmich M, Sebastian M, Schulz C, Brugger W, Wiewrodt R, Pirker R, Früh M, Gautschi O, Wolf J.

Pneumologie. 2018 Nov;72(11):774-781. doi: 10.1055/a-0647-9835. Epub 2018 Nov 8. German.

PMID:
30408830
9.

Multidisciplinary treatment of lung cancer in older patients: A review.

Radovic M, Kanesvaran R, Rittmeyer A, Früh M, Minervini F, Glatzer M, Putora PM.

J Geriatr Oncol. 2018 Oct 3. pii: S1879-4068(18)30198-X. doi: 10.1016/j.jgo.2018.09.005. [Epub ahead of print] Review.

PMID:
30292418
10.

Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01).

Früh M, Betticher DC, Stupp R, Xyrafas A, Peters S, Ris HB, Mirimanoff RO, Ochsenbein AF, Schmid R, Matzinger O, Stahel RA, Weder W, Guckenberger M, Rothschild SI, Lardinois D, Mach N, Mark M, Gautschi O, Thierstein S, Biaggi Rudolf C, Pless M; Swiss Group for Clinical Cancer Research (SAKK).

J Thorac Oncol. 2019 Jan;14(1):115-123. doi: 10.1016/j.jtho.2018.09.011. Epub 2018 Sep 26.

PMID:
30267838
11.

Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).

Schmid S, Diem S, Li Q, Krapf M, Flatz L, Leschka S, Desbiolles L, Klingbiel D, Jochum W, Früh M.

Cancer Immunol Immunother. 2018 Dec;67(12):1825-1832. doi: 10.1007/s00262-018-2239-4. Epub 2018 Aug 31.

PMID:
30171269
12.

Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.

Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.

J Thorac Oncol. 2018 Nov;13(11):1784-1791. doi: 10.1016/j.jtho.2018.08.007. Epub 2018 Aug 22.

PMID:
30142389
13.

Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study.

Leon-Reyes S, Schäfer J, Früh M, Schwenkglenks M, Reich O, Schmidlin K, Staehelin C, Battegay M, Cavassini M, Hasse B, Bernasconi E, Calmy A, Hoffmann M, Schoeni-Affolter F, Zhao H, Bucher HC.

Clin Infect Dis. 2019 Feb 15;68(5):827-833. doi: 10.1093/cid/ciy564.

PMID:
30020416
14.

Immune checkpoint inhibitors and small cell lung cancer: what's new?

Schmid S, Früh M.

J Thorac Dis. 2018 May;10(Suppl 13):S1503-S1508. doi: 10.21037/jtd.2018.01.113. Review.

15.

The role of radiation therapy in the management of small cell lung cancer.

Glatzer M, Schmid S, Radovic M, Früh M, Putora PM.

Breathe (Sheff). 2017 Dec;13(4):e87-e94. doi: 10.1183/20734735.009617. Review.

16.

Genomic Features of Response to Combination Immunotherapy in Lung Cancer.

Früh M, Peters S.

Cancer Cell. 2018 May 14;33(5):791-793. doi: 10.1016/j.ccell.2018.04.005.

PMID:
29763618
17.

EML4-ALK Variant Affects ALK Resistance Mutations.

Früh M, Peters S.

J Clin Oncol. 2018 Apr 20;36(12):1257-1259. doi: 10.1200/JCO.2017.77.2764. Epub 2018 Mar 1. No abstract available.

PMID:
29494260
18.

Glucocorticoids and the Risk of Peptic Ulcer Bleeding: Case-Control Analysis Based on Swiss Claims Data.

Reinau D, Schwenkglenks M, Früh M, Signorell A, Blozik E, Meier CR.

Drug Saf. 2018 Jul;41(7):725-730. doi: 10.1007/s40264-018-0645-3.

PMID:
29468603
19.

Treatment of limited disease small cell lung cancer: the multidisciplinary team.

Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora PM.

Eur Respir J. 2017 Aug 24;50(2). pii: 1700422. doi: 10.1183/13993003.00422-2017. Print 2017 Aug. Review.

20.

Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton AJ, Früh M.

Lung Cancer. 2017 Sep;111:176-181. doi: 10.1016/j.lungcan.2017.07.024. Epub 2017 Jul 24.

PMID:
28838390
21.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

22.

Inappropriate use of arthroscopic meniscal surgery in degenerative knee disease.

Muheim LLS, Senn O, Früh M, Reich O, Rosemann T, Neuner-Jehle SM.

Acta Orthop. 2017 Oct;88(5):550-555. doi: 10.1080/17453674.2017.1344915. Epub 2017 Jun 30.

23.

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E.

J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.

24.

Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer.

Siano M, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V.

Oncologist. 2017 Jul;22(7):782-e70. doi: 10.1634/theoncologist.2017-0069. Epub 2017 Jun 7.

25.

Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.

Ess SM, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M.

Eur J Cancer Care (Engl). 2017 Nov;26(6). doi: 10.1111/ecc.12721. Epub 2017 May 30.

PMID:
28557060
26.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

27.

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment.

Parra-Guillen ZP, Berger PB, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillessen S, Krähenbühl S, Kloft C, Joerger M.

Basic Clin Pharmacol Toxicol. 2017 Oct;121(4):309-315. doi: 10.1111/bcpt.12801. Epub 2017 Jun 19.

28.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10. Erratum in: Lancet Respir Med. 2018 Dec;6(12):e57.

PMID:
28408243
29.

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.

J Transl Med. 2017 Mar 30;15(1):66. doi: 10.1186/s12967-017-1174-z.

30.

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.

J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19.

31.

Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Früh M, Flatz L.

Oncoimmunology. 2016 Sep 19;5(11):e1231292. doi: 10.1080/2162402X.2016.1231292. eCollection 2016.

32.

Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial.

Gautschi O, Rothschild SI, Li Q, Matter-Walstra K, Zippelius A, Betticher DC, Früh M, Stahel RA, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2017 May;18(3):303-309. doi: 10.1016/j.cllc.2016.11.007. Epub 2016 Nov 23.

PMID:
27993482
33.

SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer.

Putora PM, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M.

Oncol Res Treat. 2016;39(11):681-686. Epub 2016 Oct 19.

PMID:
27855379
35.

Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, Cerny T, Joerger M.

Lung Cancer. 2016 Oct;100:38-44. doi: 10.1016/j.lungcan.2016.07.027. Epub 2016 Jul 28.

PMID:
27597279
36.

Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma.

Bickel A, Koneth I, Enzler-Tschudy A, Neuweiler J, Flatz L, Früh M.

BMC Cancer. 2016 Aug 19;16:656. doi: 10.1186/s12885-016-2718-y.

37.

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung.

Reichegger H, Jochum W, Förbs D, Hader C, Früh M.

Oncol Res Treat. 2016;39(7-8):461-3. doi: 10.1159/000446759. Epub 2016 Jun 15.

PMID:
27486808
38.

Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.

Früh M, Ris HB, Xyrafas A, Peters S, Mirimanoff RO, Gautschi O, Pless M, Stupp R.

Ann Oncol. 2016 Oct;27(10):1971-3. doi: 10.1093/annonc/mdw251. Epub 2016 Jun 29. No abstract available.

PMID:
27358380
39.

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.

Ann Oncol. 2016 Feb;27(2):281-6. doi: 10.1093/annonc/mdv573. Epub 2015 Nov 23.

PMID:
26598547
40.

Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.

Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar CB, Eckhardt K, Schmid RA, Aebersold DM, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik IF, Weder W.

Lancet Oncol. 2015 Dec;16(16):1651-8. doi: 10.1016/S1470-2045(15)00208-9. Epub 2015 Nov 2.

PMID:
26538423
41.

Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.

Pless M, Stupp R, Ris HB, Stahel RA, Weder W, Thierstein S, Gerard MA, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier UR, Mamot C, Rauch D, Gautschi O, Betticher DC, Mirimanoff RO, Peters S; SAKK Lung Cancer Project Group.

Lancet. 2015 Sep 12;386(9998):1049-56. doi: 10.1016/S0140-6736(15)60294-X. Epub 2015 Aug 11. Erratum in: Lancet. 2015 Sep 12;386(9998):1040.

PMID:
26275735
42.

Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.

Gautschi O, Milia J, Cabarrou B, Bluthgen MV, Besse B, Smit EF, Wolf J, Peters S, Früh M, Koeberle D, Oulkhouir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J.

J Thorac Oncol. 2015 Oct;10(10):1451-7. doi: 10.1097/JTO.0000000000000625.

43.

Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.

Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF; Swiss Group for Clinical Cancer Research.

Clin Lung Cancer. 2015 Sep;16(5):358-65. doi: 10.1016/j.cllc.2015.02.007. Epub 2015 Mar 5.

PMID:
25843489
44.

Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC).

Putora PM, Ess S, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M.

Clin Exp Metastasis. 2015 Feb;32(2):143-9. doi: 10.1007/s10585-015-9699-0. Epub 2015 Jan 28.

PMID:
25628027
45.

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M.

Lung Cancer. 2015 Jan;87(1):85-7. doi: 10.1016/j.lungcan.2014.11.008. Epub 2014 Nov 18.

PMID:
25466451
46.

Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer.

Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch SD, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen KJ, Gnad-Vogt U, Zippelius A.

BMC Cancer. 2014 Oct 6;14:748. doi: 10.1186/1471-2407-14-748.

47.

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).

Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M.

Lung Cancer. 2014 Aug;85(2):306-13. doi: 10.1016/j.lungcan.2014.04.014. Epub 2014 May 29.

PMID:
24928469
48.

Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis.

Diem S, Ess S, Cerny T, Früh M, Hitz F.

Eur J Intern Med. 2014 Jul;25(6):577-82. doi: 10.1016/j.ejim.2014.05.001. Epub 2014 May 28.

PMID:
24881010
49.

EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.

Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M; Swiss Group for Clinical Cancer Research.

PLoS One. 2013 Sep 10;8(9):e72966. doi: 10.1371/journal.pone.0072966. eCollection 2013.

50.

EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report.

Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C.

Case Rep Oncol. 2013 Jun 13;6(2):316-9. doi: 10.1159/000352086. Print 2013 May.

Supplemental Content

Support Center